Due to the fact that ccRCC with different genotypes may respond differently to targeted therapy, the extraction of imaging biomarkers that are capable of predicting BAP1 mutation would be of great significance for ccRCC precision therapy (14, 15). The gene discussed is BAP1; the disease is nonpapillary renal cell carcinoma.